DK2670404T3 - Sirtuinmodulatorer som virusproduktionsmodulatorer - Google Patents

Sirtuinmodulatorer som virusproduktionsmodulatorer Download PDF

Info

Publication number
DK2670404T3
DK2670404T3 DK12705543.2T DK12705543T DK2670404T3 DK 2670404 T3 DK2670404 T3 DK 2670404T3 DK 12705543 T DK12705543 T DK 12705543T DK 2670404 T3 DK2670404 T3 DK 2670404T3
Authority
DK
Denmark
Prior art keywords
sirt1
sirt2
inhibitor
rna
sirtuin
Prior art date
Application number
DK12705543.2T
Other languages
English (en)
Inventor
Thomas Shenk
Emre Koyuncu
Ileana Cristea
Original Assignee
Univ Princeton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Princeton filed Critical Univ Princeton
Application granted granted Critical
Publication of DK2670404T3 publication Critical patent/DK2670404T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Claims (13)

1. Sammensætning til anvendelse i behandling af en sygdom forårsaget af ét eller flere vira, der omfatter én eller flere hæmmere af to eller flere sirtuiner, hvor sirtuinerne er valgt fra SIRTI, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6 og SIRT7, hvor SIRTI-hæmmeren og SIRT2-hæmmeren er en dobbelt SIRTl/SIRT2-hæmmer, og hvor hæmmeren ikke er suramin.
2. Sammensætning til anvendelse ifølge krav 1, hvor den ene hæmmer hæmmer to eller flere sirtuiner.
3. Sammensætning til anvendelse ifølge krav 1 eller 2, hvor SIRTI er hæmmet.
4. Sammensætning til anvendelse i behandling af en sygdom forårsaget af et hvilket som helst eller flere vira, der omfatter en SIRTI-hæmmer og en SIRT2-hæmmer, hvor SIRTI-hæmmeren og SIRT2-hæmmeren er en dobbelt SIRTl/SIRT2-hæmmer, og hvor den dobbelte SIRT1/SIRT2-hæmmer ikke er suramin.
5. Sammensætning til anvendelse ifølge krav 4, hvor den dobbelte SIRT1/SIRT2-hæmmer er cambinol, salermid, tenovin-6, tenovin-1 eller en kombination deraf.
6. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 4-5, hvor virusset er HCMV, human papilloma virus, HSV1, FluA, adenovirus, influenza virus, hepatitis B virus, hepatitis C virus eller HIV.
7. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 4-5, hvor virusset er Adenoviridae; Hepadnaviridae; Herpesviridae; Flaviviridae; Orthomixoviridae; Papillomaviridae; Polyomaviridae eller Retroviridae.
8. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 4-7, der endvidere omfatter én eller flere af en SIRT3-, SIRT4-, SIRT5-, SIRT6- og SIRT7-agonist.
9. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 4-8, der endvidere omfatter et antivirusmiddel.
10. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-9, hvor cellen er en tumorcelle.
11. Sammensætning til anvendelse ifølge krav 10, hvor tumorcellen er inficeret med HCMV.
12. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-11, hvor de to eller flere sirtuiner hæmmes ved at hæmme genekspression af mindst én af de to eller flere sirtuiner.
13. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 4-9, hvor SIRT1-hæmmeren og SIRT2-hæmmeren administreres samtidigt.
DK12705543.2T 2011-02-02 2012-02-02 Sirtuinmodulatorer som virusproduktionsmodulatorer DK2670404T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438846P 2011-02-02 2011-02-02
US201161527102P 2011-08-24 2011-08-24
PCT/US2012/023621 WO2012106509A1 (en) 2011-02-02 2012-02-02 Sirtuin modulators as virus production modulators

Publications (1)

Publication Number Publication Date
DK2670404T3 true DK2670404T3 (da) 2018-11-19

Family

ID=45755524

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12705543.2T DK2670404T3 (da) 2011-02-02 2012-02-02 Sirtuinmodulatorer som virusproduktionsmodulatorer

Country Status (6)

Country Link
US (2) US20130338178A1 (da)
EP (1) EP2670404B1 (da)
JP (1) JP2014505705A (da)
CN (1) CN103391777A (da)
DK (1) DK2670404T3 (da)
WO (1) WO2012106509A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505705A (ja) 2011-02-02 2014-03-06 ザ トラスティーズ オブ プリンストン ユニヴァシティ ウイルス生成モジュレーターとしてのサーチュインモジュレーター
JP6120311B2 (ja) * 2013-02-12 2017-04-26 学校法人銀杏学園 ポリフェノール化合物
WO2014138562A1 (en) * 2013-03-07 2014-09-12 Glaxosmithkline Llc Thieno[3,2-d]pyrimidine-6-carboxamides and analogues as sirtuin modulators
EP3073824A4 (en) * 2013-11-25 2017-10-25 Saint Louis University Inhibitors of hsv nucleotidyl transferases and uses therefor
KR101596276B1 (ko) 2014-02-27 2016-02-22 한국화학연구원 Ｓｉｒｔ７ 단백질의 탈아세틸화 활성을 저해하는 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
CN104193644B (zh) * 2014-09-27 2015-12-02 张远强 甲氧萘环的丁二酸酰胺衍生物、其制备方法及用途
WO2016045115A1 (zh) * 2014-09-28 2016-03-31 姜凡 Hiv-1整合酶抑制剂
CN105087811A (zh) * 2015-09-18 2015-11-25 重庆医科大学 Sirt3基因的用途及其相关药物
WO2017083971A1 (en) * 2015-11-16 2017-05-26 University Of Manitoba Compositions and methods for treatment of influenza
KR20180095032A (ko) * 2015-12-17 2018-08-24 메르크 파텐트 게엠베하 신남산 유도체
US11103496B2 (en) 2016-02-22 2021-08-31 The Trustees Of The University Of Pennsylvania Methods for enhancing liver regeneration
JP2019523242A (ja) * 2016-07-01 2019-08-22 アラーキス セラピューティクス， インコーポレイテッド Ｒｎａ機能をモジュレートするための化合物および方法
JP2018024592A (ja) * 2016-08-09 2018-02-15 株式会社ブレインヘルス 抗生物質含有組成物
CN110392680A (zh) 2016-12-22 2019-10-29 拜耳作物科学股份公司 取代的唑基吡咯酮和唑基乙内酰脲及其盐及其作为除草活性物质的用途
JP7434154B2 (ja) * 2017-11-24 2024-02-20 オタゴ イノベーション リミテッド 糖尿病および関連する疾患を治療するための医薬的組合せならびに方法
WO2019109046A1 (en) 2017-11-30 2019-06-06 Arrakis Therapeutics, Inc. Nucleic acid-binding photoprobes and uses thereof
CN108042524A (zh) * 2017-12-21 2018-05-18 南方医科大学 丹酚酸b及其结构类似物在制备抗hpv病毒感染药物中的应用
CN108619123A (zh) * 2018-03-13 2018-10-09 武汉威立得生物医药有限公司 Tenovin-1在制备防治人类疱疹病毒感染药物中的应用
CN109157536A (zh) * 2018-07-26 2019-01-08 贵州万里乡村农业开发有限公司 一种鸭瘟病的防治方法
CN109394738A (zh) * 2018-12-07 2019-03-01 浙江医院 白皮杉醇在防治人巨细胞病毒感染中的新用途
CN109876144B (zh) * 2019-04-03 2019-11-22 山东大学 Emc8基因抑制剂在制备治疗胃癌药物中的用途
CN112807294B (zh) * 2019-11-18 2023-09-05 武汉大学 一种酰基硫脲类化合物在制备治疗或预防单纯疱疹病毒i型感染药物中的应用
CN113350330B (zh) * 2020-03-06 2023-04-14 中国科学院上海药物研究所 杨梅素类化合物在制备防治新冠肺炎药物中的应用
CN112516122A (zh) * 2020-04-21 2021-03-19 洪楠方 苏拉明在制备预防或治疗冠状病毒相关疾病药物中的用途
US20230293525A1 (en) * 2020-07-30 2023-09-21 University Of Connecticut Methods and compositions for the treatment of viral infections
WO2022029275A1 (en) * 2020-08-06 2022-02-10 Nuvamid Sa Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of coronavirus infections and covid-19
EP3949964A1 (en) * 2020-08-06 2022-02-09 Nuvamid SA Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of viral infections
IT202000023281A1 (it) * 2020-10-02 2022-04-02 Univ Degli Studi Del Piemonte Orientale A Avogadro Inibitore o antagonista di sirt1 per uso nella prevenzione e/o trattamento di un tumore indotto da hpv
CN114432283A (zh) * 2020-10-30 2022-05-06 中国科学院深圳先进技术研究院 Sirtinol在制备预防和治疗冠状病毒的药物中的应用
WO2022088037A1 (zh) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Sirtinol在制备预防和治疗冠状病毒的药物中的应用
WO2022192645A1 (en) * 2021-03-12 2022-09-15 The General Hospital Corporation Compounds for brain imaging
WO2023123225A1 (zh) * 2021-12-30 2023-07-06 南京紫珑生物科技有限公司 Sirt1-7蛋白在免疫治疗中的应用
WO2023159601A1 (en) * 2022-02-28 2023-08-31 Shenzhen University Use of agent deacetylating klf4 to promote transcriptional activity thereof, method for maintaining functions of pulmonary artery endothelial cells, and method for treating pulmonary arterial hypertension

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
AU5012285A (en) * 1984-10-12 1986-05-02 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav)
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
EP0260032B1 (en) 1986-09-08 1994-01-26 Ajinomoto Co., Inc. Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
AU598946B2 (en) 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5403711A (en) 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
DE3855864T2 (de) 1987-11-30 1997-09-25 Univ Iowa Res Found Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
JPH03503894A (ja) 1988-03-25 1991-08-29 ユニバーシィティ　オブ　バージニア　アランミ　パテンツ　ファウンデイション オリゴヌクレオチド　ｎ‐アルキルホスホラミデート
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5721218A (en) 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
EP0942000B1 (en) 1989-10-24 2004-06-23 Isis Pharmaceuticals, Inc. 2'-Modified oligonucleotides
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5623065A (en) 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
EP0455905B1 (en) 1990-05-11 1998-06-17 Microprobe Corporation Dipsticks for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
BR9106702A (pt) 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
IL99066A (en) 1990-08-03 1996-01-31 Sterling Winthrop Inc Nuclease-resistant compounds containing oligonucleotide sequences having either or both of the ends, and preparations containing them
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
JPH06505704A (ja) 1990-09-20 1994-06-30 ギリアド　サイエンシズ，インコーポレイテッド 改変ヌクレオシド間結合
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US7223833B1 (en) 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
DE59208572D1 (de) 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
DE637965T1 (de) 1991-11-26 1995-12-14 Gilead Sciences Inc Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen.
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
ATE155467T1 (de) 1993-03-30 1997-08-15 Sanofi Sa Acyclische nucleosid analoge und sie enthaltende oligonucleotidsequenzen
AU6412794A (en) 1993-03-31 1994-10-24 Sterling Winthrop Inc. Oligonucleotides with amide linkages replacing phosphodiester linkages
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
NZ278490A (en) 1993-12-09 1998-03-25 Univ Jefferson Chimeric polynucleotide with both ribo- and deoxyribonucleotides in one strand and deoxyribonucleotides in a second strand
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5646269A (en) 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US5912340A (en) 1995-10-04 1999-06-15 Epoch Pharmaceuticals, Inc. Selective binding complementary oligonucleotides
US6379911B2 (en) 1996-02-23 2002-04-30 Albert Einstein College Of Medicine Of Yeshiva University Enzyme detection/assay method and substrates
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CN1273476C (zh) 1997-09-12 2006-09-06 埃克西康有限公司 寡核苷酸类似物
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US6197834B1 (en) * 1998-09-01 2001-03-06 Northeastern Ohio Universities College Of Medicine Method of inhibiting formation of infectious herpes virus particles
CA2634299C (en) 1999-04-08 2011-05-31 Industrial Research Limited Process for preparing inhibitors of nucleoside metabolism
EP1072679A3 (en) 1999-07-20 2002-07-31 Agilent Technologies, Inc. (a Delaware corporation) Method of producing nucleic acid molecules with reduced secondary structure
JP2004507534A (ja) 2000-08-29 2004-03-11 インダストリアル　リサーチ　リミテッド ヌクレオシド代謝阻害剤
CA2433840C (en) 2001-01-04 2010-05-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof
AU2002356992A1 (en) 2001-11-21 2003-06-10 Albert Einstein College Of Medicine Of Yeshiva University Sir2 products and activities
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US7022680B2 (en) 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US20060014705A1 (en) 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
US20090137681A1 (en) * 2005-04-08 2009-05-28 David A Sinclair Sirtuin Inhibiting Compounds
AU2006278397B2 (en) 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
DE102007002715A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
US20100137345A1 (en) * 2007-05-14 2010-06-03 Universite Libre De Bruxelles Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
WO2010077642A1 (en) * 2008-12-08 2010-07-08 Northwestern University Method of modulating hsf-1
JP2014505705A (ja) 2011-02-02 2014-03-06 ザ トラスティーズ オブ プリンストン ユニヴァシティ ウイルス生成モジュレーターとしてのサーチュインモジュレーター

Also Published As

Publication number Publication date
WO2012106509A1 (en) 2012-08-09
CN103391777A (zh) 2013-11-13
US10813934B2 (en) 2020-10-27
EP2670404B1 (en) 2018-08-29
US20130338178A1 (en) 2013-12-19
JP2014505705A (ja) 2014-03-06
EP2670404A1 (en) 2013-12-11
US20160296523A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
DK2670404T3 (da) Sirtuinmodulatorer som virusproduktionsmodulatorer
JP5710977B2 (ja) 抗ウイルス薬としての修飾塩基を含むオリゴヌクレオチドの使用
DK2753316T3 (da) Farmaceutisk kombination omfattende et cip2a silencing-middel til anvendelse i behandlingen af en hyperproliferativ lidelse, fortrinsvis en med svækket p53-funktion
JP2019141097A (ja) タウ発現を調節するための組成物および方法
US10072263B2 (en) Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA
AU2020200247A1 (en) Organic compositions to treat KRAS-related diseases
US20140315983A1 (en) Methods and compositions for the specific inhibition of met by double stranded rna
JP2016501533A (ja) 二本鎖ｒｎａによるｃｋａｐ５の特異的阻害に関する方法および組成物
JP6001655B2 (ja) 併用療法
US11124795B2 (en) Genetic and pharmacological transcriptional upregulation of the repressed FXN gene as a therapeutic strategy for Friedreich ataxia
RU2664466C1 (ru) Композиция для лечения рака, ассоциированного с инфекцией hpv
JP7431728B2 (ja) ＥＮａＣ発現の調節因子
WO2016112374A2 (en) Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr)
AU2019206731A1 (en) Modulators of DNM2 expression
TW202309282A (zh) 抗病毒核酸
WO2021248027A1 (en) Compositions and methods of inhibiting angiotensin-converting enzyme 2 (ace2) and transmembrane serine protease 2 (tmprss2)
DK2872631T3 (da) Kombinationsterapi
JP2023161422A (ja) 二本鎖領域を有する抗ウイルス核酸
Shi et al. Antisense downregulation of SARS‐CoV gene expression in Vero E6 cells
JP2009526516A (ja) 呼吸性ウイルス感染を処置するための組成物およびその使用